Tew

Results: 140



#Item
41Shionogi Launches Injectable Analgesics for Cancer Pain, “OxiFast® Injection 10mg” and “OxiFast® Injection 50mg” Osaka, Japan, May 28, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Tesh

Shionogi Launches Injectable Analgesics for Cancer Pain, “OxiFast® Injection 10mg” and “OxiFast® Injection 50mg” Osaka, Japan, May 28, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Tesh

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:22
42Shionogi Launches “Endoxan® Powder 100mg for Oral” for Nephrotic Syndrome Osaka, Japan, July 30, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) tod

Shionogi Launches “Endoxan® Powder 100mg for Oral” for Nephrotic Syndrome Osaka, Japan, July 30, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) tod

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:23
43

PDF Document

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:24
44   	
     EZOSE	
  SCIENCES	
  FORMS	
  ALLIANCE	
  WITH	
  FAST	
  FORWARD	
   	
  TO	
  DISCOVER	
  BIOMARKERS	
  TO	
  DIAGNOSE	
  MULTIPLE	
  SCLEROSIS	
  

      EZOSE  SCIENCES  FORMS  ALLIANCE  WITH  FAST  FORWARD    TO  DISCOVER  BIOMARKERS  TO  DIAGNOSE  MULTIPLE  SCLEROSIS  

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:24
45ILDONG PHARMACEUTICAL Receives a Marketing and Manufacturing Approval for Pirespa® 200mg Tablet Idiopathic Pulmonary Fibrosis Treatment Osaka, Japan, August 8, Shionogi & Co., Ltd. (Head Office: Osaka; President:

ILDONG PHARMACEUTICAL Receives a Marketing and Manufacturing Approval for Pirespa® 200mg Tablet Idiopathic Pulmonary Fibrosis Treatment Osaka, Japan, August 8, Shionogi & Co., Ltd. (Head Office: Osaka; President:

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:25
46January 25, 2010 Shionogi & Co., Ltd. Shionogi Supports Relief Efforts for Haiti Earthquake Victims Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “Shionogi”) today announced th

January 25, 2010 Shionogi & Co., Ltd. Shionogi Supports Relief Efforts for Haiti Earthquake Victims Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President: Isao Teshirogi; hereafter “Shionogi”) today announced th

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:18
47Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside

Interim Results from SAILING Study, One of the Phase III Studies of the Integrase Inhibitor “Dolutegravir”, Disclosed by ViiV Healthcare Osaka, Japan, March 7, Shionogi & Co., Ltd. (Head Office: Osaka; Preside

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:24
48Shionogi starts a screening program for new anti-TB compounds Osaka, Japan, June 3, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that

Shionogi starts a screening program for new anti-TB compounds Osaka, Japan, June 3, Shionogi & Co., Ltd. (Head Office: Osaka; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) today announced that

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:23
49ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P

ViiV Healthcare Receives EU marketing authorization for Triumeq®, a Single-pill Regimen Containing the Integrase Inhibitor “Dolutegravir” Osaka, Japan, September 4, Shionogi & Co., Ltd. (Head Office: Osaka; P

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2015-01-27 14:49:56
50Shionogi Receives Approvals of Pediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic, ® “Finibax 0.25g/0.5g for Intravenous Drip Infusion” and “Finibax® 0.25g Kit for Intra

Shionogi Receives Approvals of Pediatric Use and Additional Indication for Purulent Meningitis of Carbapenem-Type Antibiotic, ® “Finibax 0.25g/0.5g for Intravenous Drip Infusion” and “Finibax® 0.25g Kit for Intra

Add to Reading List

Source URL: shionogi616.tew-staging.com

Language: English - Date: 2014-11-03 11:26:21